Marketing Research and Analysis

Global Biosimilars Market - Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics. Global Biosimilars Market Summary “Biosimilars” provides an in-depth assessment of the current developments and trends in the global biosimilars market. This report also assesses the state of the biosimilar R&D and commercial landscape through multilevel analytics that include data split by therapy area, stage of development, molecule, and company. Global revenue forecasts to 2024 for biosimilars with strong market potential, both in development and in the market, are provided. Data analyses from study shows that there will be enormous commercial opportunities for biosimilar manufacturers over the coming years, given the number of high-revenue-generating biologics that will go off patent in the next five years, and promising revenue forecasts for biosimilars in late-stage development. Current biosimilar regulatory framewor...

Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers. While the number of biosimilar approvals in the US still lags behind Europe, a solid foundation continues to be laid by multiple key stakeholder groups. Successes have been seen in key areas, including the approval of the first monoclonal antibody (mAb) biosimilar, Inflectra, and regulatory refinement. But what of the critical opportunities and challenges in the US? How do payers perceive what’s important, and what can companies do to ensure commercial success? WHAT FEATURES DOES THE REPORT PROVIDES? In-depth interviews reveal over 200 unique and candid insights from ten 10 expert US payers from government and commercial backgrounds Overview of the key areas of progress in the US biosimilars market during the last year, including an analysis of critical market shaping issues such as clinical data, regulatory progress, commercialisation, legal and policy. The ...